Eisai
Eisai, Biogenās Leqembi reduces amyloid in Alzheimerās, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Keytruda-Lenvima combo fails to improve survival in two lung cancer trials
Merck and Eisai’s collaborative effort with Keytruda and Lenvima faces yet another setback in their quest to combat cancer. Despite ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
Eisai Unveils Lecanemab’s Alzheimer’s Breakthrough at AAIC 2023
Source – Eisai July 20, 2023 Biogen revealed the results of a comprehensive analysis of the Phase III Clarity AD ...
How will Medicare be affected by the cost of Leqembi from Eisai and Biogen? Sen. Sanders is curious
Senator Bernie Sanders (I-Vt.) is increasing his pressure on the US Department of Health and Human Services (HHS) regarding the ...
Eisai and Biogen Embark on Full Launch of Leqembi Following Alzheimer’s Approval
Source – Eisai On July 6, 2023, Eisai and Biogen received full approval from the FDA for their Alzheimer’s disease ...
Dementia Solutions: Eisai, Gates, UK Health & Univ. Edinburgh
Source – Eisai On June 29, 2023, Eisai, Gates Ventures, Health Data Research UK, LifeArc, and The University of Edinburgh ...
Eisai has requested to approve Leqembi, its therapy for Alzheimer’s disease, in South Korea
This filing comes just before an FDA advisory committee meeting, which has raised expectations of the drug receiving full approval ...
Eisai has been targeted by a ransomware attack and has initiated an investigation into potential data breaches
Eisai, a pharmaceutical company, has become the latest victim of a ransomware attack. Following the cyberattack on Saturday night, the ...
